ProCE Banner Activity

Beamion LUNG-1 Phase Ia/Ib Study: Updated Results of HER2 TKI Zongertinib in Patients With Advanced NSCLC or Other Solid Tumors With HER2 Aberrations

Conference Coverage
Slideset

The phase I Beamion LUNG-1 trial showed tolerability and preliminary activity with the HER2 TKI zongertinib in patients with advanced solid tumors with HER2 aberrations, including previously treated NSCLC with HER2 TKD mutations.

Released: June 06, 2024

Expiration: June 05, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.